{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:41:58Z","timestamp":1794062518001,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.11.079","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T18:49:48Z","timestamp":1513018188000},"page":"559-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005\u20132015"],"prefix":"10.1016","volume":"36","author":[{"given":"Penina","family":"Haber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige W.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Hibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah F.","family":"Schillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noele P.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.11.079_b0005","unstructured":"ENGERIX-B\u00ae [Hepatitis B Vaccine (Recombinant)] Package inserts; 1983. <https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Engerix-B\/pdf>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0010","unstructured":"Recombivax HB\u00ae Hepatitis B vaccine (Recombinant) package insert; 1989. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM110114.pdf>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0015","unstructured":"Comvax\u00ae [Haemophilus b Conjugate (Meningococcal protein conjugate) and Hepatitis B (recombinant) Vaccine package insert; 1997. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM109869.pdf>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0020","unstructured":"Pediarix\u00ae [Diphtheria and Tetanus Toxoid and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine package insert; 2002. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM241874.pdf>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0025","unstructured":"Twinrix\u00ae [Hepatitis A &Hepatitis B (Recombinant) Vaccine package insert; 2001. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM110079.pdf>"},{"key":"10.1016\/j.vaccine.2017.11.079_b0030","unstructured":"Merck discontinues production of Comvax vaccine (Hib-HepB). <http:\/\/www.immunize.org\/express\/issue1136.asp#IACX6>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0035","unstructured":"Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54 (RR-16):1\u201331. <https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5516a1.htm>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0040","unstructured":"Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55(RR-16):1-33. <https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5416a1.htm#tab5>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0045","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.15585\/mmwr.mm6539a4","article-title":"Vaccination coverage among children aged 19\u201335 Months \u2014 United States, 2015","volume":"65","author":"Hill","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.11.079_b0050","unstructured":"World health organization: information sheet observed rate of vaccine reactions: Hepatitis B. June 2012 <http:\/\/www.who.int\/vaccine_safety\/initiative\/tools\/Hep_B_Vaccine_rates_information_sheet.pdf>."},{"key":"10.1016\/j.vaccine.2017.11.079_b0060","unstructured":"Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. Institute of Medicine (US) Immunization Safety Review Committee; Stratton K, Almario D, McCormick MC, editors. Washington (DC): National Academies Press (US); 2002."},{"issue":"3","key":"10.1016\/j.vaccine.2017.11.079_b0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14740338.2.3.225","article-title":"Safety of immunisation and adverse events following vaccination against hepatitis B","volume":"2","author":"Duclos","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.vaccine.2017.11.079_b0070","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1212\/WNL.64.7.1317-a","article-title":"Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study","volume":"64","author":"DeStefano","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2017.11.079_b0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0895-4356(98)00014-6","article-title":"Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)","volume":"51","author":"Niu","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2017.11.079_b0080","unstructured":"Adverse effects of vaccines: Evidence and causality. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. US: IOM (Institute of Medicine), National Academy Press; 2012."},{"key":"10.1016\/j.vaccine.2017.11.079_b0085","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The vaccine safety datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.079_b0090","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1016\/j.vaccine.2011.06.112","article-title":"Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15\u201359 years of age","volume":"29","author":"Ray","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.079_b0095","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/aje\/kws011","article-title":"Immunization and Bell\u2019s palsy in children: a case-centered analysis","volume":"175","author":"Rowhani-Rahbar","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.11.079_b0100","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/pds.1354","article-title":"Hepatitis B vaccine and risk of autoimmune thyroid disease: a vaccine safety datalink study","volume":"16","author":"Yu","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2017.11.079_b0055","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.11.079_b0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cid\/ciw224","article-title":"Case\u2013centered analysis of optic neuritis after vaccines","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2017.11.079_b0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.11.079_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/0194599816639043","article-title":"Sudden-onset sensorineural hearing loss after immunization: a case-centered analysis","volume":"155","author":"Baxter","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"36","key":"10.1016\/j.vaccine.2017.11.079_b0120","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.11.079_b0125","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2017.11.079_b0130","unstructured":"Medical Dictionary for Regulatory Activities. Medical dictionary for regulatory activities. <http:\/\/www.meddra.org\/how-to-use\/support-documentation> (accessed May 20, 2016)."},{"key":"10.1016\/j.vaccine.2017.11.079_b0135","unstructured":"Code of Federal Regulations. 21 CFR \u00a7600.80. Revised April 1, 2010. Available at <http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm? fr=600.80>."},{"issue":"6","key":"10.1016\/j.vaccine.2017.11.079_b0140","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/cid\/civ423","article-title":"Death reported to the Vaccine Adverse event reporting System, United States, 1997-2013","volume":"61","author":"Moro","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.079_b0145","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.vaccine.2017.11.079_b0150","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/00006454-200111000-00009","article-title":"Safety of neonatal hepatitis B vaccine administration. Vaccine Safety Datalink Workgroup","volume":"20","author":"Lewis","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.11.079_b0155","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.079_b0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"6","key":"10.1016\/j.vaccine.2017.11.079_b0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"48","key":"10.1016\/j.vaccine.2017.11.079_b0170","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1016\/j.vaccine.2014.09.018","article-title":"Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013","volume":"32","author":"Haber","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.079_b0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.079_b0180","unstructured":"Hibbs FB, Moro PL, Lewis P, Miller ER, Shimabukuro TT. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000\u20132013."},{"key":"10.1016\/j.vaccine.2017.11.079_b0185","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/01.inf.0000130953.08946.d0","article-title":"Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project","volume":"23","author":"Eriksen","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2017.11.079_b0190","first-page":"1","article-title":"Deaths: Leading cause of death for 2014","volume":"65","author":"Heron","year":"2016","journal-title":"Natl Vital Stat Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2017.11.079_b0195","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jpeds.2014.12.014","article-title":"Adverse events following haemophilus influenzae type b vaccines in the vaccine adverse event reporting system, 1990\u20132013","volume":"166","author":"Moro","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2017.11.079_b0200","unstructured":"Kochanek Kenneth D, Murphy Sherry L, Xu Jiaquan, Tejada-Vera Betzaida. Division of Vital Statistics. Deaths: Final Data 2014 on Sepsis (bacterial sepsis of newborn) is the seventh leading cause of death in infants in the US Volume 65, June 30, 2016. <https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr65\/nvsr65_04.pdf>."},{"issue":"6","key":"10.1016\/j.vaccine.2017.11.079_b0205","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/01.PHH.0000296128.54767.d7","article-title":"What is going on with vaccines: keeping up with the childhood immunization schedule","volume":"13","author":"Hillenbrand","year":"2007","journal-title":"J Public Health Manag Pract"},{"key":"10.1016\/j.vaccine.2017.11.079_b0210","unstructured":"Department of Health and Human Services (DHHS): Office of the inspector general. Vaccines for children program: vulnerabilities in vaccine management. June 2012. OEI 04-10-00430. p. 1\u201352."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1731722X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1731722X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:23:54Z","timestamp":1759400634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1731722X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X1731722X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005\u20132015","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}